Results 11 to 20 of about 436,066 (210)
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj +3 more sources
Parameter inference in mechanistic models of cellular regulation and signalling pathways using gradient matching [PDF]
, 2012 A challenging problem in systems biology is parameter inference in mechanistic models of signalling pathways. In the present article, we investigate an approach based on gradient matching and nonparametric Bayesian modelling with Gaussian processes.
Dondelinger, F. +7 more
core +9 more sources
The JAK-STAT Pathway and the JAK Inhibitors [PDF]
Journal of Clinical Research in Dermatology, 2020 Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription (STAT) proteins pathway for intracellular signaling, orchestrating hematopoiesis, inducing inflammation, and controlling the immune response.
Ana Paula Galli Sanchez +2 more
openaire +1 more source
JAK-STAT, 2013 The endocrine cytokine leptin is mainly secreted by white adipose tissue and plasma leptin levels positively correlate with body fat mass. Via its action on neurons in the hypothalamic arcuate nucleus (ARC), leptin regulates body weight by stimulating energy expenditure and inhibiting food intake.
Peelman, Frank, Tavernier, Jan
openaire +2 more sources
IFN‐α/β‐mediated NK2R expression is related to the malignancy of colon cancer cells
Cancer Science, Volume 113, Issue 8, Page 2513-2525, August 2022., 2022 IFN‐α/β induced neurokinin 2 receptor (NK2R), a G protein‐coupled receptor for neurokinin A in a JAK1/2‐dependent manner. NK2R expression was related to the tumorigeneis and mietastatic colonization of colon cancer cells. Therefore, NK2R blockade will be a promising strategy for colon cancers.
Huihui Xiang +13 more
wiley +1 more source
British Journal of Haematology, Volume 198, Issue 2, Page 317-327, July 2022., 2022 Summary Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts ≥50 × 109/l, based on outcomes from the phase 3, placebo‐controlled JAKARTA trial in JAK‐inhibitor‐naïve MF, and the phase 2, single‐arm JAKARTA2 trial in patients previously treated with ruxolitinib.
Claire N. Harrison +11 more
wiley +1 more source
C/EBPβ regulates the JAK/STAT signaling pathway in triple‐negative breast cancer
FEBS Open Bio, Volume 11, Issue 4, Page 1250-1258, April 2021., 2021 C/EBPβ is a b‐ZIP transcription factor. Here, we present evidence that C/EBPβ is specifically overexpressed in human TNBC samples, but not in non‐TNBC samples. C/EBPβ depletion dramatically suppresses TNBC cell growth, migration, invasion, and colony formation ability.
Shu Wang +7 more
wiley +1 more source
Oncogene, 2005 A somatic mutation that leads to activation of the JAK2 tyrosine kinase has recently been identified as a recurrent genetic abnormality in several different myeloproliferative disorders. A translocation generating the constitutively activated fusion protein PCM1-JAK2 has also been recently found in atypical chronic myelogenous leukemia and acute ...
openaire +2 more sources